Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
48.67
-1.17 (-2.35%)
At close: May 19, 2026, 4:00 PM EDT
48.60
-0.07 (-0.14%)
After-hours: May 19, 2026, 5:30 PM EDT
Exelixis Revenue
Exelixis had revenue of $610.81M in the quarter ending April 3, 2026, with 9.97% growth. This brings the company's revenue in the last twelve months to $2.38B, up 3.33% year-over-year. In the year 2025, Exelixis had annual revenue of $2.32B with 6.98% growth.
Revenue (ttm)
$2.38B
Revenue Growth
+3.33%
P/S Ratio
5.15
Revenue / Employee
$2,205,656
Employees
1,077
Market Cap
12.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.32B | 151.43M | 6.98% |
| Dec 31, 2024 | 2.17B | 338.49M | 18.49% |
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
| Dec 31, 2018 | 853.83M | 401.35M | 88.70% |
| Dec 31, 2017 | 452.48M | 261.02M | 136.34% |
| Dec 31, 2016 | 191.45M | 154.28M | 415.05% |
| Dec 31, 2015 | 37.17M | 12.06M | 48.03% |
| Dec 31, 2014 | 25.11M | -6.23M | -19.87% |
| Dec 31, 2013 | 31.34M | -16.11M | -33.96% |
| Dec 31, 2012 | 47.45M | -242.19M | -83.62% |
| Dec 31, 2011 | 289.64M | 104.59M | 56.52% |
| Dec 31, 2010 | 185.05M | 33.29M | 21.93% |
| Dec 31, 2009 | 151.76M | 33.90M | 28.76% |
| Dec 31, 2008 | 117.86M | 4.39M | 3.87% |
| Dec 31, 2007 | 113.47M | 14.80M | 15.00% |
| Dec 31, 2006 | 98.67M | 22.71M | 29.90% |
| Dec 31, 2005 | 75.96M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.44B |
| Genmab | 3.90B |
| BioMarin Pharmaceutical | 3.24B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Ascendis Pharma | 998.25M |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
EXEL News
- 13 hours ago - Exelixis Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 14 hours ago - Exelixis announces clinical development collaboration with Merck - TheFly
- 14 hours ago - Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer - Business Wire
- 7 days ago - Exelixis Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 12 days ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May - Business Wire
- 12 days ago - Exelixis price target raised to $56 from $54 at H.C. Wainwright - TheFly
- 12 days ago - Exelixis price target raised to $50 from $49 at Morgan Stanley - TheFly
- 12 days ago - Exelixis price target raised to $47 from $44 at Stifel - TheFly